Levera 250 Tablet contains Levetiracetam 250 mg, an antiepileptic medication primarily used to manage partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing neuronal activity and preventing seizure propagation. It is indicated as adjunctive therapy for epilepsy in adults and pediatric patients aged one month and older. Levera 250 is well-absorbed orally, with rapid onset of action and minimal protein binding, making it suitable for various patient populations, including those with hepatic impairment. The drug is generally well-tolerated; common adverse effects include somnolence, dizziness, headache, and fatigue, while serious side effects are rare but may involve behavioral changes or hypersensitivity reactions. Dose adjustments may be necessary in renal impairment. Levera 250 should be used under medical supervision, with gradual dose titration to minimize adverse effects. It is important to adhere to prescribed dosing schedules and not discontinue therapy abruptly to avoid increased seizure frequency. Levera 250 offers an effective and well-established option for seizure control, improving patient quality of life when integrated into comprehensive epilepsy management.